Oxaprozin - Indication, Dosage, Precautions, Side Effects, and Pharmacological Aspects

Overview:

Oxaprozin is a nonsteroidal anti-inflammatory medicine (NSAID) used to treat moderate to severe pain and arthritis symptoms, including inflammation, edema, stiffness, and joint discomfort (including rheumatoid arthritis, juvenile rheumatoid arthritis, and osteoarthritis).

For Patients:

What Are the Side Effects of Oxaprozin?

The common side effects of the drug are listed below:

• Vomiting.

• Bloating of the stomach.

• Dizziness and drowsiness.

• Diarrhea.

• Constipation.

• Pain in the head.

• Difficulty sleeping.

• Ringing sound in the ears.

• Depression and confusion.

The serious side effects of the drug are:

• Swelling is seen on the face, lips, eyes, throat, hands, or tongue.

• Difficulty breathing and swallowing.

• Blisters and fever.

• Itching and rashes.

• Stomach upset and appetite loss.

• Increased heartbeat and pale skin.

• Painful urination.

• Lack of energy.

• Discolored, dark, and brown urine.

How Is the Medicine Stored and Disposed Of?

The medicine must be kept in the original, tightly secured container. It is essential to store it in a location inaccessible to children. The drug should be kept in a location without excessive heat and moisture, especially in the bathroom. Safety caps must be secured immediately after using the medication. Prescriptions that have not been used must be appropriately disposed of to keep dogs, children, and others from consuming them. The medication should, however, always be retained in the bathroom. Instead, using a drug take-back program is the best way to dispose of the medicines. The chemist or the city's recycling department can provide more information regarding the take-back program. One can also visit the FDA (Food and Drug Administration) website for the safe disposal of medicines to learn more about the take-back program.

What Specific Safety Measures Should Be Taken?

• Inform the physician and pharmacist about any drug allergies, including those to Oxaprozin, Aspirin, other NSAIDs like Ibuprofen and Naproxen, other drugs, or any inactive components in Oxaprozin tablets.

• Inform the doctor if the patient has had asthma, heart failure, swollen hands, feet, ankles, lower legs, renal disease, or liver illness.

• The patient should inform the doctor if they are expecting, want to get pregnant, or are nursing a baby. Oxaprozin may damage the fetus and complicate delivery if it is used beyond 20 weeks of pregnancy. Except as directed by the physician, avoid using Oxaprozin during or after the first 20 weeks of pregnancy. Call the doctor if the patient becomes pregnant while taking Oxaprozin.

How Does the Patient Take Oxaprozin?

Oxaprozin is available in the form of a tablet to be swallowed. Typically, it is taken two or three times a day. Every day, take Oxaprozin around the indicated time. Patients should ask the physician or chemist to clarify instructions on the prescription label they are unsure about following. The dosage should be taken as prescribed by the doctor.

For Doctors:

What is Oxaprozin Used For?

Oxaprozin is used to:

• Treat moderate to severe pain.

• Manage symptoms of rheumatoid arthritis.

• Relieve juvenile rheumatoid arthritis.

• Alleviate osteoarthritis-related symptoms.

• Reduce inflammation, swelling, stiffness, and joint discomfort.

• Improve mobility in patients with chronic joint conditions.

What Are the Pharmacological Aspects of Oxaprozin?

Physical Properties of the Drug:

• Color - White to off-white with a slight odor.

• Drug Group - NSAIDs (nonsteroidal anti-inflammatory drugs).

• Chemical Name - 4,5-diphenyl-2-oxazole-propionic acid

• Empirical Formula - C18H15NO3.

• Molecular Weight - 293.

• PKA in Water (Acid Dissociation Constant) - 4.3.

• Melting Point - 162 to 163 degrees Celsius.

• Solubility - Does not dissolve in water but is soluble in alcohol.

• Components of the Drug - Starch, polyethylene glycol, titanium dioxide, magnesium stearate, hypromellose, methylcellulose, and microcrystalline cellulose.’

Mechanism of Action:

The oxaprozin mechanism of action involves inhibiting the production of prostaglandins, which mediate inflammation and pain. Oxaprozin reduces swelling, eases pain, and lowers fever by targeting the prostaglandin synthetase enzyme. Although its exact pathway remains under research, its anti-inflammatory, analgesic, and antipyretic properties have been well-documented in clinical studies. Its structure and unique pharmacokinetics allow for a prolonged half-life, making once- or twice-daily dosing effective.

Pharmacodynamics:

The drug Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that has been shown in animal models to have anti-inflammatory, analgesic, and antipyretic effects. Like other NSAIDs, the exact mechanism of action of Oxaprozin is unknown. However, it may be connected to prostaglandin synthetase inhibition.

Pharmacokinetics:

• Absorption - After oral dosing, Oxaprozin is 95 percent absorbed. The absorption rate is slowed by food, but the amount of absorption remains unaffected. Antacids have no discernible impact on how quickly or thoroughly Oxaprozin is absorbed.

• Distribution - The estimated volume of distribution (Vd/F) for the entire amount of Oxaprozin in the body is roughly 11 to 17 liters per 70 kilograms of body weight.In plasma, albumin is the plasma protein to which Oxaprozin is 99 percent attached. At therapeutic medication doses, Oxaprozin's plasma protein binding is saturable, resulting in an increasing amount of the free drug as the overall drug concentration increases. The observed distribution volume and the clearance of the total amount increased with higher single doses or repeated once-daily dosing. In contrast, unbound drug clearance declined due to nonlinear protein binding. According to its physical-chemical characteristics, Oxaprozin is predicted to be secreted in human milk, although the quantity of Oxaprozin secreted in breast milk is yet to be assessed. In patients with rheumatoid arthritis, Oxaprozin has been found to enter synovial tissues, with concentrations approximately two-fold higher than in plasma and three-fold higher than in synovial fluid.

• Metabolism - Human urine or feces have been shown to contain several Oxaprozin metabolites. The metabolites of Oxaprozin do not have considerable pharmacologic action. In individuals with appropriate renal function, metabolites do not build up in the plasma even after prolonged doses. Plasma only has relatively small concentrations of the metabolites. The liver is Oxaprozin's main site of metabolism, carrying out microsomal oxidation (65 percent) and glucuronic acid conjugation (35 percent). The two most important conjugated metabolites of Oxaprozin are ether glucuronide and ester. For in vivo animal models and receptor binding experiments, the ester and ether glucuronide conjugated metabolites have been assessed alongside Oxaprozin and have shown little action. Active phenolic metabolites are created in a negligible quantity (five percent), although they contribute very little to total activity.

• Excretion - Around five percent of Oxaprozin is eliminated unaltered in the urine. 65 percent of the dosage is eliminated as metabolites in the urine and 35 percent in the feces. The enterohepatic recycling of Oxaprozin is negligible, and biliary excretion of unaltered Oxaprozin is a minor route. The accumulating half-life after chronic dosage is around 22 hours. Due to higher binding and reduced clearance at lower concentrations, the elimination half-life is typically two times longer than the accumulation half-life.

Oxaprozin Pharmacological Details:

Oxaprozin structure is defined by its chemical composition, 4,5-diphenyl-2-oxazole-propionic acid. With a molecular weight of 293, it is part of the NSAID drug group and exhibits properties that make it highly effective for long-term arthritis management.

What Should I Know About Oxaprozin Before Using It?

• It may interact with other medications like aspirin, methotrexate, or diuretics, which could increase the risk of side effects.

• Avoid using it in the later stages of pregnancy, as it might harm the baby.

• Always talk to your doctor about your health and any medicines you’re taking before starting Oxaprozin.

What Should I Tell My Healthcare Provider Before Using Oxaprozin?

It is essential to inform your doctor or pharmacist about your complete medical history before starting Oxaprozin.

• Have any allergies, especially to oxaprozin, aspirin, or other NSAIDs.

• Suffer from asthma, cardiovascular disease, liver or kidney problems, or gastrointestinal disorders.

• Take medications that could interact with Oxaprozin, such as blood thinners, ACE inhibitors, or certain diuretics.

• If you are pregnant, breastfeeding, or planning to conceive, inform your healthcare provider, as Oxaprozin may not be safe during specific stages of pregnancy. Accurate communication ensures the oxaprozin dose prescribed is appropriate and minimizes risks.

Drug Use in Specific Populations:

• Pediatric Population - A population pharmacokinetic study found no clinically significant age-dependent changes in the apparent clearance of unbound Oxaprozin between adult and juvenile rheumatoid arthritis patients.

• Geriatric Population - As with any NSAID, care should be taken when managing elderly people (65 years and older). Although many older people may require a lower dose due to low body weight or problems linked to aging, there is no need to change the dosage for pharmacokinetic reasons.

• Hepatic Insufficiency - 95 percent of Oxaprozin is metabolized by the liver. There is no difference in the Oxaprozin dose that must be administered in patients with well-compensated cirrhosis compared to individuals with normal hepatic function. Hence, they do not need lower doses of Oxaprozin. However, individuals with significant hepatic impairment should be treated with care.

• Cardiac Failure - Oxaprozin's pharmacokinetics and plasma protein binding are unaffected by well-compensated heart failure.

• Renal Insufficiency:

  • Only five percent of an Oxaprozin dosage is eliminated without any changes in the urine. Oxaprozin's renal clearance reduces proportionally to creatinine clearance (CrCl). Patients with renal insufficiency have been studied for pharmacokinetics and treated with Oxaprozin.

  • The clinical significance of the reduction in total body clearance of Oxaprozin arises in those with severely reduced CrCl. Due to its strong protein binding, Oxaprozin is not considerably eliminated from the blood in patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

  • Patients with significant renal impairment may see a reduction in Oxaprozin's plasma protein binding and may require dosage modifications.

What Should I Do in Case of an Overdose or Missed Dose?

If you miss a dose of Oxaprozin, take it as soon as you remember, unless it’s almost time for your next scheduled dose. In such cases, skip the missed dose and continue your regular dose schedule. Never double the dose to make up for a missed one. In the case of an overdose, symptoms may include severe nausea, vomiting, dizziness, or difficulty breathing. Seek immediate medical attention or contact a poison control center. Always store oxaprozin tablets and other dosages securely to prevent accidental ingestion, especially by children.

What Are the Indications and Contraindications of Oxaprozin?

• Indications:

  • Indicated to treat juvenile rheumatoid arthritis, rheumatoid arthritis, and osteoarthritis.

• Contraindications:

  • Patients with known Oxaprozin hypersensitivity should not use Oxaprozin.

  • Oxaprozin is not indicated for managing perioperative pain during coronary artery bypass graft (CABG) surgery.

  • Patients with asthma, urticaria, or allergic-like symptoms after taking aspirin or other NSAIDs should not be given Oxaprozin, as NSAIDs have been linked to severe, rarely deadly anaphylactic responses in such people.

Warnings and Precautions:

• Cardiovascular Thrombotic Event - A higher incidence of major cardiovascular (CV) thrombotic events, stroke, and myocardial infarction, which can be fatal, has been seen in clinical studies of numerous COX-2 selective and nonselective NSAIDs for up to three years. There may be a comparable risk with all COX-2 selective and nonselective NSAIDs. Patients with known cardiovascular disease or risk factors for developing it may be more susceptible. Two significant, controlled clinical studies of a COX-2 selective NSAID discovered an increased risk of stroke and myocardial infarction. It was given for pain management for the first few days (usually 10 to 14 days) after CABG surgery.

• Hypertension - Some people using NSAIDs have had fluid retention and edema. Patients with fluid retention or heart failure should take Oxaprazin cautiously. NSAIDs, such as Oxaprozin, may cause new hypertension or exacerbate pre-existing hypertension, which may raise the risk of CV events. Patients with hypertension should use NSAIDs, especially Oxaprozin, with care. Blood pressure (BP) should be constantly monitored when starting NSAID medication and for its duration.

• Congestive Heart Failure and Edema - Some people using NSAIDs have reported fluid retention and edema. People with fluid retention or heart failure should use Oxaprozin with care.

• Gastrointestinal Effects - NSAIDs, especially Oxaprozin, can result in severe gastrointestinal (GI) adverse effects, including in the stomach, small intestine, or large intestine. It results in ulceration, rupture, bleeding, and inflammation. These severe negative effects can happen to people using NSAIDs at any moment, with or without prior warning signs. The lowest effective dose should be administered for the shortest possible time to reduce GI events in individuals receiving an NSAID. During treatment with Oxaprozin, patients and doctors should be vigilant for signs and symptoms of GI bleeding and ulceration and start extra testing and therapy as soon as a significant GI event is detected. This involves discontinuing the NSAID until a significant gastrointestinal adverse event is ruled out. Alternative treatments without the use of NSAIDs have to be taken into consideration for high-risk individuals.

• Renal Effects - NSAID use over an extended period has caused renal papillary necrosis and other renal damage. Patients in whom renal prostaglandins are compensatory in maintaining renal perfusion have also experienced renal toxicity. Nonsteroidal anti-inflammatory medication therapy in these individuals may result in a dose-dependent decrease in prostaglandin production and, secondarily, renal blood flow, which may lead to overt renal decompensation. Patients with poor renal function, heart failure, liver dysfunction, those on diuretics and ACE inhibitors, and the elderly are those who are most at risk of this reaction. Recovery to the pre-treatment state frequently follows the cessation of NSAID medication.

• Anaphylactic Reactions - Similar to other NSAIDs, Oxaprozin can cause anaphylactoid responses in people who have never taken it. Patients experiencing the aspirin triad should not take Oxaprozin. This symptom cluster is most common in asthmatic patients with rhinitis, whether or not they have nasal polyps or individuals with severe bronchospasm after taking aspirin or other NSAIDs, including Oxaprozin.

• Skin - Oxaprozin can cause deadly toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome, and exfoliative dermatitis, among other significant side effects. These clinical manifestations occur suddenly, and patients should be educated about them.

• Pregnancy - The ductus arteriosus may close too soon due to exposure to Oxaprozin; hence, it should be avoided.

What Are the Drug Interactions of Oxaprozin?

• Aspirin - Aspirin and Oxaprozin should not be used together because Oxaprozin removes salicylates from plasma protein binding sites. The risk of salicylate toxicity is anticipated to rise with coadministration.

• Methotrexate - Studies suggest that co-administration of Oxyprozin and Methotrexate increases its toxicity. When Oxyprozin and Methotrexate are administered together, the oral clearance of Methotrexate is reduced by around 36%. Since Oxyprozin exposure increases Methotrexate, the dosage of Methotrexate may be reduced.

• ACE Inhibitors - NSAIDs may diminish the antihypertensive action of ACE inhibitors. Enalapril and its active metabolite, Enalaprilat, have been demonstrated to have altered pharmacokinetics when administered with Oxaprozin. When patients use NSAIDs and Angiotensin-converting enzyme inhibitors together, this interaction should be taken into account.

• Diuretics - According to clinical trials and post-marketing findings, the natriuretic effects of Furosemide and Thiazides can be lessened in certain people by Oxyprozin. This reaction has been linked to renal prostaglandin production suppression. The patient should be cautiously watched for indications of renal failure while receiving concurrent NSAID medication.

• Warfarin - Due to the synergistic effects of warfarin and NSAIDs on gastrointestinal (GI) bleeding, people who take both medications have a larger risk of experiencing significant GI bleeding than those who take either alone.

• Beta-Blockers - NSAIDs tend to increase blood pressure. Hence, as with any NSAID, patients commencing Oxaprozin medication should take routine blood pressure monitoring into account.

• H2 Receptor Antagonist - In patients receiving therapeutic dosages of Cimetidine or Ranitidine at the same time as Oxaprozin, the total body clearance of Oxaprozin was lowered by 20 percent. No changes were noticed in other pharmacokinetic parameters.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Oxaprozin did not exhibit any mutagenicity or fertility impairment in trial studies. However, a trial study on male and female mice showed carcinogenicity. The male mice showed increased cases of liver cancer. However, the result is known among humans.

Dosage and Administration:

For each patient's unique treatment objectives, use the smallest dose that will be active for the shortest time. After evaluating each patient's first response to Oxaprozin, the dose and frequency should be changed to meet each patient's needs.

• Rheumatoid Arthritis - The typical dose for rheumatoid arthritis treatment is 1200 milligrams. Two 600 mg caplets are taken daily orally.

• Juvenile Rheumatoid Arthritis (JRA) - Based on the patient's body weight, a suggested dose should be administered orally once a day to patients aged 6 to 16 to manage the signs and symptoms of JRA.

What Are the Adverse Reactions of Oxaprozin?

• CVS or Cardiovascular System - Edema.

• Hematological System - Increase in bleeding duration and anemia.

• Nervous System - CNS inhibition (depression, sedation, somnolence, disorientation), headache, and dizziness.

• Digestive System - Abdominal discomfort, diarrhea, gastrointestinal ulcers (gastric or duodenal), dyspepsia, flatulence, anorexia, constipation, extensive bleeding or perforation, nausea, vomiting, elevated liver enzymes, and heartburn.

• Urogenital System - Dysuria (painful urination), and impairment of renal function.

• Skin - Rashes and itching.

Clinical Trial Study and Drug Efficacy:

For three months, 40 patients with active rheumatoid arthritis participated in a parallel, double-blind experiment to examine the anti-inflammatory efficacy and adverse effects of therapy with Oxaprozin and Aspirin. The findings demonstrated that in rheumatoid arthritis, 1200 mg of Oxaprozin daily has anti-inflammatory characteristics comparable to those of 3.9 g of Aspirin. Better outcomes were obtained with a daily dose of 1200 mg Oxaproxin than a dose level of 600 mg, indicating a tight dose-response relationship. Similar side effects were reported for both Oxaprozin and Aspirin. While rash and headache were more frequently reported in individuals on Oxaprozin, gastrointestinal discomfort was more frequent and severe in the Aspirin group.